High risk of hepatitis B virus reactivation among patients treated with direct-acting antivirals and coinfected with HCV and HIV
- PMID: 31811829
- DOI: 10.1016/j.jinf.2019.11.018
High risk of hepatitis B virus reactivation among patients treated with direct-acting antivirals and coinfected with HCV and HIV
Keywords: DAA; HBV reactivation; HCV; HIV–HCV coinfection.
Conflict of interest statement
Declaration of Competing Interest Authors declare that there is no conflict of interest.
Comment on
-
Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 vs 12 weeks.J Infect. 2019 Jul;79(1):30-35. doi: 10.1016/j.jinf.2019.05.005. Epub 2019 May 14. J Infect. 2019. PMID: 31100364
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
